Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta, Y Núñez… - International Journal …, 2021 - Taylor & Francis
Background and Purpose Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta, Y Núñez… - International Journal …, 2021 - dovepress.com
Background and Purpose: Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta… - International …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and purpose Around 40-50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
[HTML][HTML] Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta, Y Núñez… - International Journal …, 2021 - ncbi.nlm.nih.gov
Background and Purpose Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta… - International …, 2021 - search.proquest.com
Background and Purpose: Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific cytotoxic effect of an auristatin nanoconjugate towards cxcr4+ diffuse large b-cell lymphoma cells
A Falgàs, V Pallarès, U Unzueta… - International …, 2021 - portalrecerca.uab.cat
Background and Purpose: Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta Elorza… - International Journal of …, 2021 - ddd.uab.cat
Around 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory
disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL …
disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL …
[PDF][PDF] Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4 Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta, Y Núñez… - International Journal …, 1869 - scienceopen.com
Background and Purpose: Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells.
A Falgàs, V Pallarès, U Unzueta, Y Núñez… - International Journal …, 2021 - europepmc.org
Background and purpose Around 40-50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
A Falgàs, V Pallarès, U Unzueta, Y Núñez… - International Journal …, 2021 - dovepress.com
Background and Purpose: Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …